vs
Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and Voyager Technologies, Inc. (VOYG). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $35.2M, roughly 1.1× Voyager Technologies, Inc.). Voyager Technologies, Inc. runs the higher net margin — -130.4% vs -161.8%, a 31.4% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 2.1%). Voyager Technologies, Inc. produced more free cash flow last quarter ($-66.8M vs $-71.3M).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
IBRX vs VOYG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $35.2M |
| Net Profit | $-61.9M | $-45.9M |
| Gross Margin | 99.0% | -4.4% |
| Operating Margin | -169.0% | — |
| Net Margin | -161.8% | -130.4% |
| Revenue YoY | 407.0% | 2.1% |
| Net Profit YoY | -4.7% | -64.5% |
| EPS (diluted) | $-0.06 | $-0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $35.2M | ||
| Q4 25 | $38.3M | $46.7M | ||
| Q3 25 | $32.1M | $39.6M | ||
| Q2 25 | $26.4M | $45.7M | ||
| Q1 25 | $16.5M | — | ||
| Q4 24 | $7.6M | — | ||
| Q3 24 | $6.1M | — |
| Q1 26 | — | $-45.9M | ||
| Q4 25 | $-61.9M | $-33.0M | ||
| Q3 25 | $-67.3M | $-16.3M | ||
| Q2 25 | $-92.6M | $-31.4M | ||
| Q1 25 | $-129.6M | — | ||
| Q4 24 | $-59.2M | — | ||
| Q3 24 | $-85.7M | — |
| Q1 26 | — | -4.4% | ||
| Q4 25 | 99.0% | 21.4% | ||
| Q3 25 | 99.4% | 15.4% | ||
| Q2 25 | 99.5% | 18.0% | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | -169.0% | — | ||
| Q3 25 | -173.5% | -60.7% | ||
| Q2 25 | -269.8% | -52.8% | ||
| Q1 25 | -390.1% | — | ||
| Q4 24 | -919.0% | — | ||
| Q3 24 | -1314.3% | — |
| Q1 26 | — | -130.4% | ||
| Q4 25 | -161.8% | -70.7% | ||
| Q3 25 | -209.8% | -41.1% | ||
| Q2 25 | -350.3% | -68.7% | ||
| Q1 25 | -784.9% | — | ||
| Q4 24 | -783.4% | — | ||
| Q3 24 | -1404.0% | — |
| Q1 26 | — | $-0.75 | ||
| Q4 25 | $-0.06 | $-0.52 | ||
| Q3 25 | $-0.07 | $-0.28 | ||
| Q2 25 | $-0.10 | $-1.23 | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | $-0.08 | — | ||
| Q3 24 | $-0.14 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.8M | $429.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-500.5M | $404.5M |
| Total Assets | $501.9M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $429.4M | ||
| Q4 25 | $242.8M | $491.3M | ||
| Q3 25 | $257.8M | $413.3M | ||
| Q2 25 | $153.7M | $468.9M | ||
| Q1 25 | $61.6M | — | ||
| Q4 24 | $149.8M | — | ||
| Q3 24 | $130.4M | — |
| Q1 26 | — | $404.5M | ||
| Q4 25 | $-500.5M | — | ||
| Q3 25 | $-524.3M | $590.9M | ||
| Q2 25 | $-570.7M | $554.7M | ||
| Q1 25 | $-591.4M | — | ||
| Q4 24 | $-489.1M | — | ||
| Q3 24 | $-745.1M | — |
| Q1 26 | — | $1.0B | ||
| Q4 25 | $501.9M | — | ||
| Q3 25 | $519.0M | $727.8M | ||
| Q2 25 | $402.1M | $685.3M | ||
| Q1 25 | $303.8M | — | ||
| Q4 24 | $382.9M | — | ||
| Q3 24 | $364.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-70.4M | $-39.7M |
| Free Cash FlowOCF − Capex | $-71.3M | $-66.8M |
| FCF MarginFCF / Revenue | -186.2% | -189.5% |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-308.8M | $-263.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-39.7M | ||
| Q4 25 | $-70.4M | $-60.9M | ||
| Q3 25 | $-68.9M | $-15.1M | ||
| Q2 25 | $-79.7M | $-30.9M | ||
| Q1 25 | $-85.9M | — | ||
| Q4 24 | $-85.1M | — | ||
| Q3 24 | $-98.8M | — |
| Q1 26 | — | $-66.8M | ||
| Q4 25 | $-71.3M | $-54.5M | ||
| Q3 25 | $-69.6M | $-53.8M | ||
| Q2 25 | $-80.8M | $-88.8M | ||
| Q1 25 | $-87.0M | — | ||
| Q4 24 | $-87.3M | — | ||
| Q3 24 | $-101.6M | — |
| Q1 26 | — | -189.5% | ||
| Q4 25 | -186.2% | -116.9% | ||
| Q3 25 | -217.2% | -135.8% | ||
| Q2 25 | -305.9% | -194.4% | ||
| Q1 25 | -526.9% | — | ||
| Q4 24 | -1155.4% | — | ||
| Q3 24 | -1663.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.3% | 97.8% | ||
| Q2 25 | 4.1% | 126.7% | ||
| Q1 25 | 6.8% | — | ||
| Q4 24 | 28.0% | — | ||
| Q3 24 | 45.7% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
